A 3-year-old child with multi-drug resistant epilepsy responding to pharmacological and nonpharmacological treatments

Int J Neurosci. 2023 Mar;133(3):322-326. doi: 10.1080/00207454.2021.1916488. Epub 2022 May 25.

Abstract

Introduction: Despite the development of new antiseizure drugs (ASDs), around one third of epilepsy patients become refractory to treatment or experience adverse events due to ASDs. Therefore, discovery of new ASDs and new therapy options are crucial to improve the quality of life. Herein, we report a 3-year-old child with multi-drug resistant epilepsy caused by perinatal asphyxia whose seizures were reduced by 90% after the introduction of ketogenic diet, vagal nerve stimulation (VNS) AspireSR (SR-seizure response) and oral cannabidiol.Case presentation: A 9-month-old female infant had a history of multidrug resistant epilepsy due to perinatal asphyxia. At admission, she was experiencing up to 20-25 seizures per day lasting for 2-3 minutes. In addition to antiseizure drugs (ASDs), she was put on ketogenic diet (KD), vagal nerve stimulation (VNS) aspire seizure response (AspireSR) was inserted and oral cannabidiol (CBD) was started sequentially. Using pharmacological and nonph armacological therapies, her seizures have been reduced by 90%.Conclusion: The concurrent use of pharmacological and nonpharmacological therapies may be beneficial to improve seizures in infants with multi- Furthermore, our patient is the youngest child inserted VNS AspireSR in Turkey.

Publication types

  • Case Reports

MeSH terms

  • Asphyxia
  • Cannabidiol* / therapeutic use
  • Child, Preschool
  • Drug Resistant Epilepsy* / drug therapy
  • Epilepsy* / drug therapy
  • Female
  • Humans
  • Infant
  • Quality of Life
  • Seizures / drug therapy
  • Seizures / etiology
  • Treatment Outcome

Substances

  • Cannabidiol